Back to results
US 2018/0021344 A1Published application
Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
AssigneeEssentialis, Inc.
InventorNeil M. COWEN
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeEssentialis, Inc.
InventorNeil M. COWEN
Estimating the term…
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
1-28. (canceled)
A method of increasing by at least 2% the lean body mass or the lean body mass/fat mass ratio in a subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS), comprising administering to the subject for at least 10 weeks a pharmaceutical formulation comprising an effective amount of a KATP channel opener or a pharmaceutically acceptable salt thereof, wherein said lean body mass or lean body mass/fat ratio in the subject is increased by at least 2% after 10 weeks of administration compared to lean body mass or lean body mass/fat ratio prior to the start of the administration.
Dependencies are inferred from the claim text.